soliris NMOSD

NMOSD medication not recommended for the PBS for a second time

Soliris® (eculizumab), the first TGA-approved medication for NMOSD, has not been recommended for listing on the PBS.

ATA188: Improvements in progressive MS maintained in extension of initial trials

New imaging data shows sustained improvement in disability and increases in myelin density in the brain following an experimental treatment for progressive MS.
rohan greenland

A note from our CEO: Rohan Greenland – December

CEO Rohan Greenland gives an update on the MS Australia activities for December, focusing on the year ahead for MS Australia.
The May 50K 2021

Thank you for raising over $5.3 million for MS research in 2021

We look back on the enormous milestones reached in 2021 thanks to the Kiss Goodbye to MS community. Thank you for continuing to accelerate our superpower – MS research.
NDIS support

Does NDIS support match the level of disability needs for people with MS?

A recent study from regional NSW is the first to assess if the NDIS package allocated to people with MS matches the level of disability measured by a formal neurological assessment. 
myelin cell neuron

What drives myelin damage in MS?

A new study of brain tissue has found that immune cells derived from blood immune cells, attack myelin in the very early stages of MS.

Reflecting on International Day of People with Disability 2021

MS Australia National Advocate Erin Brady reflects on International Day of People with Disability in a post-pandemic world.
Kiss Goodbye to MS Ambassadors

The inspiring Australians who are making a difference

Our Kiss Goodbye to MS ambassadors say thank you to the fantastic MS community by sharing their very own thank you letters.
remyelination MS

Is a naturally occurring molecule the key to remyelination?

MS researchers have investigated whether a naturally occurring molecule, which some DMTs mimic, has the capacity to promote myelin repair.
2021 prime awards

MS Australia shortlisted for 2021 Prime Awards

CEO Rohan Greenland gives an update on the MS Australia activities for November, focusing on MS Australia's 2021 Prime Award nomination.
sun UV radiation

Nature’s fingolimod: how UV radiation suppresses autoimmunity

New research funded by MS Australia has shown how UV light traps immune cells in the lymph nodes, similar to the action of some MS therapies.
incubator grants 2021

MS Australia announces funding of ‘outside the box’ ideas

MS Australia has funded seven new innovative MS research projects totalling nearly $150,000 in this year’s first round of incubator grants.
AHSCT MS cells

Real-world follow up study of AHSCT for MS

A study has followed the progress of over 500 people with MS who have undergone AHSCT for up to 5 years after the procedure.
john studdy award

MS Australia’s prestigious John Studdy Award 2020 announcement

MS Australia Chair of the John Studdy Award panel, Sharlene Brown, is delighted to announce the 2020 John Studdy Award winner is Mr Ian Pennell AM.

About AHSCT – current thinking

There have been recent positive steps forward for people with MS considering AHSCT. Read the current thinking towards AHSCT for people with MS.
future of ms research

Research conferences: shaping the future of MS

CEO Rohan Greenland gives an update on the MS Australia activities for October, focusing on the world's largest MS research conference ECTRIMS and the importance of conferences in shaping the future of MS.
Sarah’s tribute to MS research

Sarah’s tribute to MS research

In 2015 Sarah's life changed completely when she was diagnosed with multiple sclerosis, she is now on a mission to raise funds to power MS research.
MS fatigue

Does “MS fatigue” capture the symptom experience?

The International Progressive MS Alliance has recently highlighted that very little progress has been made in treating and understanding MS fatigue.

Newsletter subscription

  • Enter your details

NMOSD medication not recommended for the PBS for a second time